Compare NDAQ & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDAQ | IDXX |
|---|---|---|
| Founded | 1971 | 1983 |
| Country | United States | United States |
| Employees | 9613 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1B | 43.6B |
| IPO Year | 2001 | 1996 |
| Metric | NDAQ | IDXX |
|---|---|---|
| Price | $88.52 | $557.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $105.62 | ★ $721.67 |
| AVG Volume (30 Days) | ★ 2.8M | 540.3K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 60.10 | 22.59 |
| EPS | 0.91 | ★ 3.47 |
| Revenue | $4,277,000,000.00 | ★ $4,303,702,000.00 |
| Revenue This Year | $10.52 | $10.88 |
| Revenue Next Year | $8.17 | $8.59 |
| P/E Ratio | ★ $95.40 | $160.94 |
| Revenue Growth | 7.87 | ★ 10.42 |
| 52 Week Low | $77.09 | $507.55 |
| 52 Week High | $101.79 | $769.98 |
| Indicator | NDAQ | IDXX |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 48.56 |
| Support Level | $86.04 | $549.60 |
| Resistance Level | $89.04 | $589.82 |
| Average True Range (ATR) | 1.94 | 15.07 |
| MACD | -0.35 | 0.70 |
| Stochastic Oscillator | 34.17 | 29.20 |
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.